Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43

Reuters03-27

Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43

Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update (link).
Q4 net loss was USD 6.6 million, while R&D expense rose 7% to USD 4.6 million.
FY net loss was USD 26.6 million and R&D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.
FY G&A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.
Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622896708?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622896708","market":"fut","top_or_hot":-1,"title":"Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update (link).\n        </li>\n<li>\n          Q4 net loss was USD 6.6 million, while R&amp;D expense rose 7% to USD 4.6 million.\n        </li>\n<li>\n          FY net loss was USD 26.6 million and R&amp;D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.\n        </li>\n<li>\n          FY G&amp;A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.\n        </li>\n<li>\n          Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update (link).\n        </li>\n<li>\n          Q4 net loss was USD 6.6 million, while R&amp;D expense rose 7% to USD 4.6 million.\n        </li>\n<li>\n          FY net loss was USD 26.6 million and R&amp;D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.\n        </li>\n<li>\n          FY G&amp;A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.\n        </li>\n<li>\n          Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLqfJV9:1","article_id":"2622896708","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622896708","pubTimestamp":1774556339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update .Q4 net loss was USD 6.6 million, while R&D expense rose 7% to USD 4.6 million.FY net loss was USD 26.6 million and R&D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.FY G&A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc.","BK4082":"医疗保健设备"},"translate_title":"Vivani Medical 2025财年净亏损扩大13.2%至2660万美元；每股亏损维持在0.43美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43\n    \n\n\n          Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update (link).\n        \n\n          Q4 net loss was USD 6.6 million, while R&D expense rose 7% to USD 4.6 million.\n        \n\n          FY net loss was USD 26.6 million and R&D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.\n        \n\n          FY G&A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.\n        \n\n          Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622896708","isCrawlerRequest":true}